KPRX · Kiora Pharmaceuticals Inc · Metrics
Market Cap
$11.72M
Shares
4.42M
KPRX metrics
55 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$2.65
Market cap
$11.72M
Price action
20 metricsPrice change (1W)
+3.9%
Price change (30D)
+3.9%
Price change (3M)
+3.9%
Price change (6M)
+26.8%
Price change (YTD)
+34.5%
Price change (1Y)
-1.9%
Trailing year
Price change (5Y)
—
52-week high
$2.86
52-week low
$1.80
Change from 52-week high
-7.3%
Change from 52-week low
+47.2%
Annualized volatility
59.5%
Annualized volatility (3M)
36.7%
Beta
1.0
RSI (14D)
55.8
Price vs SMA 50
+3.2%
Price vs SMA 200
+13.2%
Avg volume (3M)
20,091
Relative volume
0.5
Average dollar volume
$51,422
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
4.42M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.7
reciprocal yield 143.8%
FCF yield
-73.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-93.7%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$12.83M
Net income (TTM)
−$10.99M
Trailing 12 months
Diluted EPS (TTM)
$-2.50
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
-401.4%
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
-403.4%
Shares change YoY
+54.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-65.2%
Return on assets
-46.2%
Debt / equity
—
Current ratio
9.0
EBITDA (TTM)
−$12.79M
Free cash flow (TTM)
−$8.61M
Quick ratio
9.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$7.08M
Total assets
$23.78M
Total debt
$278,190
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$8.51M
Capital expenditures (TTM)
$107,068
R&D (TTM)
$9.86M
SG&A (TTM)
—
Stock compensation (TTM)
$807,666
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
22
13F filer change QoQ
+1
Institutional ownership
25.8%
Short interest
3 metricsShort interest
0.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
40 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—